To validate the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer on the survival of patients who underwent radical hysterectomy for 2009 FIGO stage IB carcinomas. We retrospectively identified and reviewed 251 patients treated with radical hysterectomy for 2009 FIGO stage IB cervical carcinomas from January 2011 to December 2016. The re-staged IB cohort consisted of 2018 FIGO stage IB1 (tumor size <2 cm), IB2 (2–3.9 cm), IB3 (≥4 cm), and IIIC1p (any pelvic nodal metastasis) cervical cancer. The univariate log-rank test and multivariate Cox regression models were performed for all potential clinic pathological risk factors based on cancer stage. On re-staging the 251 patients with 2009 FIGO stage IB using the 2018 FIGO staging system, 96 patients (38.2%) had stage IB1, 109 patients (43.4%) had stage IB2, 28 patients (11.2%) had stage IB3, and 18 patients (7.2%) had stage IIIC1p. The 5-year overall survival (OS) rates of patients with 2018 FIGO stage IB1, IB2, IB3, and IIIC1p were 97.9%, 92.7%, 78.6%, and 61.1%, respectively. The 5-year progression-free survival rates were 97.9%, 92.7%,63.7%, and 20.8%, respectively. Factors significantly affecting OS and disease-free survival were 2018 FIGO stage≥IB3, histologic grade 2–3, and lymph node involvement. The revised 2018 FIGO staging system seemed to accurately reflect the survival rate, with a distinct statistical tendency for poorer 5-year disease-free survival and OS rates with increasing stage. Women with positive lymph nodes in this classification were classified as having stage IIIC disease, which can achieve more realistic survival results than the previous staging system. The prognostic discrimination of histologic grade should be considered when revising the staging system in the future.
Purpose: In combined intracavitary/interstitial (IC/IS) gynecologic brachytherapy, trackers attached to interstitial needles of localize real-time needle trajectories, and intraoperative ultrasound (US) images provide updated anatomy information during needle insertions. To achieve an effective visualization and image guidance, real-time needle trajectories and US images can be unified in preoperative magnetic resonance imaging (MRI) image space together. This study evaluates the rigid registration accuracy between US images and MRI images as well as the registration accuracy between US images and real-time needle trajectories in a pelvic phantom. Material and methods: A method for US probe calibration and accomplished rigid registration between MRI images and US images was proposed. An IC/IS applicator was designed. Micro electromagnetic sensor to track and localize real-time needle trajectories in 3D MRI image space was used. Marker validation to test the accuracy of US probe calibration and pelvic phantom validation to test the registration accuracy between US images and MRI images was conducted as well as and pelvic phantom study to verify the registration accuracy between real-time needle trajectories and needle trajectories in registered US images. Results: US probe calibration accuracy was 0.80 ±0.23 mm (n = 60). Registration accuracy between US images and MRI images were 1.01 ±0.22 mm in the axial plane (n = 60) and 1.14 ±0.20 mm in the sagittal plane (n = 24). Registration accuracy between real-time needle trajectories and needle trajectories in registered US images were 1.25 ±0.31 mm (n = 40) and 1.61 ±0.28 degrees (n = 5), respectively. Conclusions: In this study, we showed that under ideal conditions, rigid registration between MRI images and US images obtained high accuracy for real-time image guidance. Additionally, registered US images provided accurate image guidance during visual needle insertion in IC/IS gynecologic brachytherapy to achieve a combination of effective visualization and image guidance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.